Patient info Open main menu

FLUORIDE 2800 PPM TOOTHPASTE - summary of medicine characteristics

Dostupné balení:

Summary of medicine characteristics - FLUORIDE 2800 PPM TOOTHPASTE

SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE MEDICINAL PRODUCT

Fluoride 2800 ppm Toothpaste

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 g of toothpaste contains 2.8 mg fluoride (as sodium fluoride), corresponding to 2800 ppm fluoride.

For the full list of excipients, see section 6.1.

PHARMACEUTICAL FORM

Toothpaste.

Smooth white paste.

CLINICAL PARTICULARS

4.1 Therapeutic indications

For the prevention and treatment of dental caries (coronal and root) in adults and children over 10 years.

4.2 Posology and method of administration

Posology

Children under 10 years old: not recommended.

Adults and children over 10 years old: Use daily instead of the normal toothpaste.

The usual dosage is to apply a 1 cm line of paste across the head of a toothbrush and brush the teeth thoroughly for one minute morning and evening. Spit out after use; for best results do not drink or rinse for 30 minutes.

Elderly: use as for adults.

Method of administration

For dental use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Individuals with known sensitivities should consult their dentist before using.

Not to be used in children under 10 years old.

4.4 Special warnings and precautions for use Not to be swallowed.

4.5 Interaction with other medicinal products and other forms of interaction None known.

4.6 Fertility, pregnancy and lactation

Epidemiological studies in humans indicate that fluoride has no adverse effects in pregnancy or on the health of the foetus or newborn child.

No effects during pregnancy are anticipated, since systemic exposure to Sodium Fluoride is negligible. Fluoride 2800 Toothpaste can be used during pregnancy.

No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Sodium Fluoride is negligible. Fluoride 2800 Toothpaste can be used during breast-feeding.

4.7 Effects on ability to drive and use machines

Fluoride 2800 ppm Toothpaste has no influence on the ability to drive and use machines.

4.8 Undesirable effects

When used as recommended there are no side effects.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

4.9 Overdose

Symptoms:

In very high doses, fluoride can have an acute toxic effect. Doses of several milligrams of fluoride per kg of body weight may cause nausea, vomiting, and diarrhoea. Tetany and convulsion can occur, as well as cardiovascular disorders.

Increased risk of bone fracture and skeletal fluorosis (stiffness of joints and skeletal deformities) will only be observed in cases of very high chronic intake of fluoride.

Management:

Treatment and management should be symptomatic.

In case of mild gastrointestinal overdose symptoms a small glass of milk to drink should be given to bind fluoride ion.

It should be noted that gut decontamination is contraindicated. Charcoal is of no benefit.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: caries prophylactic agents, ATC code: A01AA01

This product is a toothpaste in which the active ingredient is Sodium Fluoride present at a level of 0.619% which corresponds to 280 mg fluoride per 100 g paste.

Sodium fluoride applied topically after tooth eruption reduces caries by inhibiting demineralisation and promoting remineralisation of the tooth surface. It is effective on both enamel and exposed dentine.

5.2 Pharmacokinetic properties

This product is not intended to be swallowed and therefore only minimal systemic exposure is expected.

5.3 Preclinical safety data

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Glycerol (E 422)

Purified Water

Sorbitol, liquid (non-crystallizing) (E 420)

Silicas

Polyethylene glycol 600

Sodium lauryl sulphate

Sodium carboxymethyl­cellulose (E 467)

Mint Flavour

Titanium dioxide (E 171)

Sodium saccharin (E954)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

75 ml polyethylene/a­luminium/poly­ethylene laminated tube with a polypropylene screw closure. Pack sizes: 1 × 75ml tube or 2 × 75ml tubes.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Colgate-Palmolive (UK) Limited

Guildford Business Park

Middleton Road

Guildford

Surrey

GU2 8JZ

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 00049/0056

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

13/03/2017